Skip to content

Castle Biosciences CSTL Balance Sheet Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$63.76M-28.9%$116.73M-2.5%$85.56M-9.9%$82.23M-3.9%$89.69M+8.1%
$5.6M-96.9%$5.59M$5.58M-97.0%$184.81M+6.1%$183.33M+17.3%
$42.26M-25.0%$43.38M-15.3%$49.48M-1.5%$52.31M+13.7%$56.35M+32.0%
$10.46M+52.7%$10.25M+26.0%$8.65M+31.6%$8.37M+4.4%$6.85M-10.4%
$328.9M-5.9%$361.1M+0.3%$357.57M+3.7%$348.67M+8.8%$349.39M+18.1%
$100.93M+82.1%$97.44M+90.6%$84.89M+91.3%$74.06M+91.7%$55.42M+68.4%
$10.7M0.0%$10.7M0.0%$10.7M0.0%$10.7M0.0%$10.7M0.0%
$86.66M+28.9%$88.88M-7.0%$91.16M-8.7%$93.43M-8.5%$67.21M-35.6%
$547.81M+9.2%$578.56M+8.9%$562.79M+9.4%$544.73M+11.8%$501.72M+9.4%
$15.04M+76.9%$18.71M+171%$12.21M+79.3%$13.18M+38.2%$8.5M-8.8%
$1.67M+50.0%$417K+50.0%$0$1.94M$1.11M
$48.76M+30.8%$68.68M+39.0%$55.31M+24.9%$50.89M+29.0%$37.27M+16.6%
$8.4M-5.9%$9.64M-1.1%$10.05M+0.3%$8.1M$8.92M
$86.39M+40.7%$107.68M+42.8%$95.74M+30.2%$89.35M+40.9%$61.41M+9.6%
$30K+3.4%$30K+7.1%$29K+3.6%$29K+3.6%$29K+3.6%
-$238.81M-5.7%-$224.28M-12.1%-$221.95M-5.8%-$221.45M-4.5%-$225.97M-2.3%
$461.42M+4.8%$470.87M+3.3%$467.05M+5.9%$455.38M+7.4%$440.31M+9.4%
$547.81M+9.2%$578.56M+8.9%$562.79M+9.4%$544.73M+11.8%$501.72M+9.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Castle Biosciences's total assets?
Castle Biosciences (CSTL) holds $547.8M in total assets, up 9.2% year over year.
How much debt does Castle Biosciences have?
Castle Biosciences carries $36.7M in total debt against $461.4M of shareholders' equity, a debt-to-equity ratio of 0.08.
How much cash does Castle Biosciences have?
Castle Biosciences holds $63.8M in cash and equivalents.
Can Castle Biosciences cover its short-term obligations?
Its current ratio is 6.75 — current assets exceed current liabilities.
Where does Castle Biosciences's balance sheet data come from?
Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.